KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Other financing activities (2016 - 2022)

Abbott Laboratories' Other financing activities history spans 7 years, with the latest figure at $324.0 million for Q1 2022.

  • For Q1 2022, Other financing activities rose 6.58% year-over-year to $324.0 million; the TTM value through Sep 2025 reached $324.0 million, up 427.27%, while the annual FY2025 figure was -$82.0 million, N/A changed from the prior year.
  • Other financing activities for Q1 2022 was $324.0 million at Abbott Laboratories, up from -$536.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $324.0 million in Q1 2022 and bottomed at -$536.0 million in Q4 2021.
  • The 5-year median for Other financing activities is $106.0 million (2019), against an average of $87.5 million.
  • The largest annual shift saw Other financing activities crashed 341.51% in 2020 before it soared 146.48% in 2021.
  • A 5-year view of Other financing activities shows it stood at $81.0 million in 2018, then rose by 4.94% to $85.0 million in 2019, then crashed by 401.18% to -$256.0 million in 2020, then plummeted by 109.38% to -$536.0 million in 2021, then soared by 160.45% to $324.0 million in 2022.
  • Per Business Quant, the three most recent readings for ABT's Other financing activities are $324.0 million (Q1 2022), -$536.0 million (Q4 2021), and $113.0 million (Q3 2021).